Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Nephron. 2022;146(4):327-334. doi: 10.1159/000520362. Epub 2021 Dec 20.
We aimed to evaluate therapeutic response and long-term renal outcomes of childhood idiopathic steroid-resistant nephrotic syndrome (iSRNS).
We retrospectively reviewed treatment regimens, especially calcineurin inhibitor (CNI), pathologic diagnoses, and long-term renal outcomes of iSRNS patients for 30 years.
Of 516 patients with idiopathic NS, 52 (10.1%) had iSRNS. Renal biopsies from 48 patients showed minimal change disease (MCD) in 23 (47.9%), focal segmental glomerulosclerosis in 24 (50.0%), and mesangioproliferative glomerulonephritis in 1 (2.1%). The median follow-up period was 66.5 (range, 4-275) months, and 90.4% of them were treated with a CNI. CNI induced remission in 70.2% within 50.4 ± 43.5 days. Of the patients with MCD and focal segmental glomerular sclerosis (FSGS), 86.4% (19/22) and 45.0% (9/20) (p = 0.005) responded to CNI, respectively. Mean time until remission after using CNI was longer with FSGS (90.4 ± 54.0 days) than with MCD (29.6 ± 26.3 days) (p = 0.010). CNI-responsive patients with FSGS or MCD showed preserved renal function, and CNI nonresponsive MCD patients also showed preserved renal function during follow-up. However, end-stage renal disease (ESRD) progressed in 8 out of 11 patients with FSGS nonresponsive to the CNI for an average of 44.9 ± 18.4 months after diagnosis.
Different response rates and times for remission were achieved with the CNI according to the pathology of iSRNS. All MCD patients regardless of CNI response and all CNI-responsive patients with FSGS showed excellent renal outcomes, while almost all FSGS patients nonresponsive to CNI eventually progressed to ESRD.
评估儿童特发性类固醇耐药性肾病综合征(iSRNS)的治疗反应和长期肾脏结局。
我们回顾性分析了 30 年来 iSRNS 患者的治疗方案,特别是钙调神经磷酸酶抑制剂(CNI)、病理诊断和长期肾脏结局。
在 516 例特发性 NS 患者中,52 例(10.1%)为 iSRNS。48 例患者的肾活检显示微小病变性肾病(MCD)23 例(47.9%),局灶节段性肾小球硬化症 24 例(50.0%),系膜增生性肾小球肾炎 1 例(2.1%)。中位随访时间为 66.5(范围 4-275)个月,90.4%的患者接受 CNI 治疗。CNI 在 50.4±43.5 天内诱导 70.2%的缓解。MCD 和局灶节段性肾小球硬化症(FSGS)患者中,86.4%(19/22)和 45.0%(9/20)(p=0.005)对 CNI 有反应。使用 CNI 后缓解的平均时间在 FSGS(90.4±54.0 天)长于 MCD(29.6±26.3 天)(p=0.010)。FSGS 或 MCD 对 CNI 有反应的患者肾功能保存,随访期间 CNI 无反应的 MCD 患者肾功能也保存。然而,11 例 FSGS 患者中有 8 例对 CNI 无反应,平均在诊断后 44.9±18.4 个月进展为终末期肾病(ESRD)。
根据 iSRNS 的病理,CNI 实现了不同的缓解率和缓解时间。所有 MCD 患者,无论 CNI 反应如何,以及所有 CNI 反应性 FSGS 患者,肾功能均良好,而几乎所有对 CNI 无反应的 FSGS 患者最终均进展为 ESRD。